Functional assays, including CCK‐8 and colony formation tests, confirmed that silencing ATP6V1E1 markedly reduced the proliferative capacity of HCC cells, highlighting its potential as a therapeutic target (Figure 8D–F). The gene discussed is ATP6V1E1; the disease is hepatocellular carcinoma.